How to Evaluate Chinese Surgical Robots: A Guide for Overseas Surgeons and Hospitals

Start With the Clinical Procedure, Not the Manufacturer's Nationality

Chinese companies now offer robotic systems for laparoscopic, orthopedic, neurosurgical, dental and selected other procedures. Their product architectures, evidence bases and commercial maturity vary considerably. For hospitals considering one of these systems, the central question is whether the specific product, configuration and clinical indication meet the institution's requirements.

A regulatory certificate, a successful demonstration procedure, a published clinical series and an installed commercial system each provide useful but different information. None should be used as a substitute for the others.

The following framework can support an initial assessment by surgeons, operating-room managers, clinical engineering teams and distributors. It is not a replacement for formal regulatory, clinical or procurement review.

1. Verify the Exact Product and Authorized Indications

Begin with the manufacturer's legal name, product model, software version, accessories and the intended clinical use stated in its registration or authorization documents. A company may have approval for one surgical specialty and be studying another. A newer version of a system may not have the same authorization status as an older model.

NMPA approval is authorization for China; it is not authorization for Europe or the United States. For European deployment, check the applicable EU MDR conformity documentation, notified-body certificate where required, authorized indications and labeling. For the United States, identify the exact FDA authorization or clearance and its scope. For other jurisdictions, review the relevant national regulator's documentation.

Ask the manufacturer to supply the certificate number, model, regulatory holder, current instructions for use and confirmation that the intended instruments are included in the authorized configuration.

2. Establish What the Robot Actually Does

Product descriptions can blur the line between navigation, robotic positioning and robotic execution. These technologies may all be clinically useful, but they have different capabilities and risk profiles.

For a laparoscopic platform, examine the control console, robotic arms, endoscope control, instrument articulation, energy integration and the surgeon's ability to recover from unexpected events. For orthopedic systems, determine whether the system provides image-based planning, instrument guidance, bone preparation, active constraints or direct robotic execution of selected steps.

Navigation-only platforms should not be treated as equivalent to arm-based surgical robots when comparing robotic capabilities or industry sales counts.

3. Read the Clinical Evidence for Your Procedure

Evidence should be evaluated at the level of the intended procedure, rather than by an undifferentiated company-wide case count. Relevant questions include:

· Was the study prospective or retrospective, randomized or observational?

· Were patients treated with the marketed product version and intended instruments?

· How many surgeons and centers participated, and what was their prior robotic experience?

· Which outcomes were reported: complications, conversion to open surgery, procedure time, blood loss, accuracy, length of stay or patient-reported outcomes?

· Was follow-up long enough for the intervention and were adverse events fully reported?

· Were comparisons appropriately adjusted for patient characteristics and learning curves?

A first-in-human study establishes early feasibility, not necessarily comparative effectiveness. High-volume single-center experience may demonstrate technical capability but can be difficult to reproduce elsewhere. Published evidence should be reviewed alongside applicable professional guidelines and local hospital requirements.

4. Test Operating-Room Workflow and Training

A robotic platform becomes part of an operating-room system. Teams should assess docking and undocking time, the working space required, patient positioning, instrument exchange, anesthesia access, emergency conversion, sterilization and turnover between cases.

Ask for a structured training plan covering surgeons, nurses, biomedical engineers and instrument-processing staff. Proctoring availability, simulation tools, credentialing expectations and the number of early supervised cases should be discussed before procurement.

A live demonstration is most useful when the case and operating conditions resemble the procedures the hospital actually performs.

5. Calculate the Full Cost Per Procedure

The headline equipment price can be a poor proxy for lifetime operating cost. Evaluate capital cost or lease payments together with maintenance, upgrades, instruments, reusable-device lifetime, cleaning and sterilization, service coverage, training and expected annual utilization.

For a meaningful comparison, calculate scenarios based on low, expected and high annual procedure volumes. Include the effect of cancelled cases, instrument supply delays and downtime. A hospital planning 100 cases a year will have different economics from one planning 500.

Payment arrangements matter as well. A system's ability to generate revenue or receive insurance reimbursement varies by country and procedure. China's own developing price-item framework for robotic assistance is an example of how regulatory approval and hospital utilization economics can diverge.

6. Evaluate Local Support and Supply Continuity

A manufacturer may have credible technology and strong domestic clinical references without yet having a mature support operation in the buyer's country. Before committing, verify:

· local field-service personnel and documented response arrangements;

· spare parts availability and instrument lead times;

· preventive maintenance and software-update procedures;

· cybersecurity, clinical data handling and system backup procedures;

· complaint, vigilance and recall processes;

· training materials in the hospital's working language;

· contractual arrangements if a distributor changes or ceases operations.

For remote-surgery applications, additional assessment is needed for communication latency, redundancy, fail-safe behavior, allocation of clinical responsibility, cross-border regulations and informed consent. A technical demonstration of remote control does not establish routine deployability.

7. Compare Regulatory, Clinical and Commercial Maturity Separately

A practical evaluation matrix uses three dimensions:

Regulatory maturity: exact approved indications, markets, configurations and post-market obligations.

Clinical maturity: procedure-specific published evidence, multi-center experience, adverse-event reporting, training and repeatability.

Commercial maturity: installations relevant to the buyer's market, instrument availability, service capability, manufacturer stability and total cost of ownership.

Scores in one dimension should not automatically be transferred to the others. A newly authorized system may have excellent engineering but limited clinical follow-up. A mature platform may carry higher costs but offer a more established training and service ecosystem.

Are Chinese Surgical Robots Safe?

There is no responsible country-level answer. Safety depends on the particular product, indication, engineering safeguards, clinical evidence, trained users, hospital systems and post-market performance. Regulatory authorization provides one necessary reference point, while published clinical evidence and local support provide additional information.

China's surgical robotics sector is developing quickly, and some companies are already reporting overseas shipments and authorizations. Buyers should request verifiable, model-specific evidence and assess it under the same clinical and commercial standards used for any other surgical robotics manufacturer.

For additional sector context, see MedChina's 2025 China Surgical Robot Sales Annual Report and 2025 NMPA Approvals of Chinese Surgical Robotic Systems.

October 29, 2026